FDA cGMP Requirements for PET Drugs

被引：0

|

作者：

Norenberg, Jeffrey P.

Schwarz, Sally

VanBrocklin, Henry

机构：

来源：

JOURNAL OF NUCLEAR MEDICINE | 2011年 / 52卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

引用

收藏

页码：16N / 16N

页数：1

相关论文

共 50 条

[1] The New FDA Pregnancy Labeling Requirements for Drugs
Frederiksen, Marilynn C.
JOURNAL OF MIDWIFERY & WOMENS HEALTH, 2011, 56 (03) : 303 - 307
[2] Postmarketing requirements for new drugs approved by the FDA
Reactions Weekly, 2022, 1895 (1) : 8 - 8
[3] CGMP for PET Drugs: Important Steps to Take Now
VanBrocklin, Henry
Schwarz, Sally
JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (12) : 17N - 17N
[4] FDA relaxes cardiovascular trial requirements for diabetes drugs
Asher Mullard
Nature Reviews Drug Discovery, 2020, 19 (5) : 298 - 298
[5] FDA relaxes cardiovascular trial requirements for diabetes drugs
Mullard, Asher
NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (05) : 298 - 298
[6] FDA moves closer to new requirements for NTI drugs
Traynor, Kate
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2011, 68 (17) : 1568 - 1570
[7] PET drugs and cGMP: Challenges within the new regulatory framework
Gameiro, Cristiana
Amaral, Horacio
Amaral, Andres
Schmitz, Alexander
Poria, Rahul
Freifelder, Richard
JOURNAL OF NUCLEAR MEDICINE, 2012, 53
[8] FDA requirements for cGMP compliance and the consequences - Report of "Pharma Congress Production and Technics 2006"
Martin, Harald
PHARMAZEUTISCHE INDUSTRIE, 2006, 68 (06): : 756 - 760
[9] FDA cGMP 483解析
苏丽花
化工与医药工程, 2015, 36 (06) : 34 - 39
[10] FDA proposes CGMP revisions
不详
CHEMICAL ENGINEERING PROGRESS, 2008, 104 (01) : 10 - 12

← 1 2 3 4 5 →